Skip to main content

Table 4 Univariate and multivariate analyses of factors affecting risk of radiation pneumonitis of Grade 2 or more and discontinuation of durvalumab Univariate analysis

From: Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

Variables

 

N

6 M cumulative incidence of G2RP (%)

p value

6 M cumulative incidence of discontinuation of Durvalumab due to G2RP (%)

p value

 

Gender

Male

37

48.7

0.038

21.6

0.03

 
 

Female

19

18.6

 

0.0

  

Pulmonary Fibrosis Score

≥ 2

10

90.0

 < 0.001

60.0

 < 0.001

 
 

0–1

46

28.3

 

4.3

  

Smoking history

Present

45

46.5

0.031

17.8

0.14

 
 

Never

11

9.0

 

0.0

  

Lung V40

≥ 10%

30

57.3

0.011

20.0

0.21

 
 

 < 10%

26

16.7

 

7.7

  

Initial PTV

≥ 398 ml

24

58.3

0.024

25.0

0.048

 
 

< 398 ml

32

23.8

 

6.3

  

Multivariate analysis

Variables

 

HR

95% CI

p value

HR

95% CI

p value

Pulmonary Fibrosis Score

≥ 2

7.83

3.38–18.13

 < 0.001

5.89

1.53–22.68

 < 0.001

Lung V40

≥ 10%

3.17

1.09–9.19

0.034

   

Initial PTV

    

2.62

0.71–9.71

0.15

  1. Lung V40 percentage of the lung volume exceeding x Gy, Lung Vs5 volume of the lung received less than 5 Gy, HR hazard ratio, PTV planning target volume